safranal has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ansari, AM; Ashrafian, S; Ghassempour, A; Jensen, P; Larsen, MR; Nawrocki, A; Rezadoost, H; Zarrineh, M | 1 |
| Ansari, AM; Ashrafian, S; Farahmand, L; Ghassempour, A; Jensen, P; Larsen, MR; Nawrocki, A; Rezadoost, H; Zarrineh, M | 1 |
2 other study(ies) available for safranal and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Comprehensive proteomics and sialiomics of the anti-proliferative activity of safranal on triple negative MDA-MB-231 breast cancer cell lines.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Cyclohexenes; Glycopeptides; Humans; Proteomics; Terpenes; Triple Negative Breast Neoplasms | 2022 |
Quantitative Phosphoproteomics and Acetylomics of Safranal Anticancer Effects in Triple-Negative Breast Cancer Cells.
Topics: Apoptosis; Cyclohexenes; Humans; Terpenes; Triple Negative Breast Neoplasms | 2022 |